Strategic partnerships Strengthen co-development opportunities with Ypsomed’s growing collaboration ecosystem, including expanded BD Neopak XtraFlow syringe programs and SCHOTT Pharma partnerships to offer integrated self-administration solutions for chronic disease therapies.

Global expansion Target US market entry and capacity-building support as Ypsomed expands facilities in California and Texas, presenting openings for local manufacturing, logistics partnerships, and regulatory-compliance services to support rapid scale and nearshore capabilities.

Digital integration Leverage Ypsomed’s ready-to-integrate digital health services and tech stack to propose end-to-end connected device ecosystems, including data capture, remote monitoring, and software-enabled therapy management for pharma/biotech clients.

Clinical acceleration Position to assist pharma partners with the Clear-to-Clinic program to de-risk and accelerate clinical trials, offering specialized support in device integration, regulatory readiness, and streamlined manufacturing handoffs for autoinjector platforms.

Design leadership Capitalize on award-winning product design like the YpsoLoop platform to differentiate offerings, proposing premium, user-centric self-injection solutions to manufacturers seeking enhanced patient adherence and improved therapy experience.